Combined results from two Phase 3 studies presented at the American College of Gastroenterology Annual Scientific Meeting (ACG) in Orlando, Fla., demonstrated that TAK-390MR resulted in higher healing rates than lansoprazole among patients with more severe grades of erosive esophagitis (EE). TAK-390MR combines dexlansoprazole with a Dual Delayed Release™ (DDR) formulation, designed to provide two separate releases of drug for extended duration of acid suppression.
FULL STORY

Source: Pharma Industry / Biotech Industry News From Medical News Today